Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor f...
Q2 2026
Aug 6, 2026
Q1 2026
May 14, 2026
FY 2025
Feb 24, 2026
Q4 2025
Q3 2025
Nov 6, 2025